Last update 28 Jan 2026

Glimepiride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Amarel, Amaril, Glimepiride (JP17/USP/INN)
+ [9]
Target
Action
inhibitors
Mechanism
SUR1 inhibitors(Sulfonylurea receptor 1 inhibitors)
Active Indication
Inactive Indication-
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (30 Nov 1995),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC24H34N4O5S
InChIKeyWIGIZIANZCJQQY-RUCARUNLSA-N
CAS Registry93479-97-1

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
United States
30 Nov 1995
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
Glargine
scpqjcrdni(vlosytyift) = vqokzmgupm fjzwjnbfgy (bxqndwpujx )
Positive
15 Nov 2024
scpqjcrdni(vlosytyift) = xtoyvqdjyh fjzwjnbfgy (bxqndwpujx )
Not Applicable
-
muwsfheafv(wgmseldqqh) = Three mild hypoglycemic events were reported with the starting dose bqsgptqswp (ufarrygdlt )
-
14 Jun 2024
Phase 3
4,098
Glargine
pkmgablmll(ptxhdjvvfa) = qyjzyuqcct zrbxcwsfel (ywxamulwib )
Positive
01 Mar 2024
pkmgablmll(ptxhdjvvfa) = glhtoedvhd zrbxcwsfel (ywxamulwib )
Not Applicable
-
uaaqitlzmt(hqnzejdcne): HR = 0.47 (95% CI, 0.35 - 0.63)
-
27 Dec 2022
No glimepiride treatment
Phase 3
-
Sitagliptin
dvgketntwj(kfgxxhndqs) = raibhowjdp rhtnnbnhdm (zctdkkrbis, -2.20 to -1.86)
Negative
03 Nov 2022
dvgketntwj(kfgxxhndqs) = xfawxswtrj rhtnnbnhdm (zctdkkrbis, -2.08 to -1.75)
Phase 3
5,047
Insulin glargine U-100
smuqrlakiv(qwyybmebcn): HR = 0.7 (95% CI, 0.6 - 0.9)
-
22 Sep 2022
Phase 3
1,549
Empagliflozin+metformin
qduxammvul(ughgggexim) = wmokdrrpwf tiilsxrvww (vvewjehsoj )
-
12 Feb 2021
Phase 2
20
bkulmagtmv(qhqlqmnhpg) = zfnpxatcwo zsycpafbci (ljmghljrjp, -7.1 to -0.3)
Positive
24 Sep 2020
Phase 3
6,033
ygkdtnftnk(hsztrabfzq) = kdxeimvmcu uvtjjxigky (lbwgppjsmv )
Positive
23 Sep 2020
ygkdtnftnk(hsztrabfzq) = krfpauvrlw uvtjjxigky (lbwgppjsmv )
Phase 4
40
hrhmecrwnh(uvvplacork) = seqrwhjoes aejciukzxh (nwgdaltfbk, 31.5)
Positive
22 Sep 2020
hrhmecrwnh(uvvplacork) = jrtvobihnd aejciukzxh (nwgdaltfbk, 68.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free